Levothyroxine — the small, color-coded pill that roughly 23 million Americans swallow every morning — is the single most prescribed medication in the United States. And in 2025, the FDA confirmed what many patients had long suspected about at least one manufacturer’s supply: the pills were subpotent, meaning they contained less active thyroid hormone than the label promised. The FDA upgraded a recall of more than 160,000 bottles of levothyroxine sodium tablets to Class II on July 23, 2025, after stability testing revealed that products manufactured by Intas Pharmaceuticals for Accord Healthcare were losing potency over time. For the millions who depend on precise dosing to keep their metabolism, mood, and cognitive function on track, this was not a minor labeling error. It was a direct threat to their health.
This recall is not an isolated incident. Between 2018 and 2021, Acella Pharmaceuticals shipped batches of NP Thyroid that contained too much or too little active hormone — a quality control failure so severe it resulted in a $46.5 million class action settlement. Meanwhile, a Yale School of Medicine analysis has raised an entirely different concern: that as many as 90% of levothyroxine users may have been prescribed the drug unnecessarily in the first place. For readers of this site, the stakes are particularly pointed. Thyroid dysfunction is closely linked to cognitive decline, and undertreated or improperly treated hypothyroidism can mimic or accelerate symptoms of dementia. This article covers the scope of the 2025 recall, the history of thyroid medication failures, what the overprescribing research actually found, and what patients and caregivers should do right now.
Table of Contents
- How Many Americans Take Levothyroxine, and Why Is Underdosing So Dangerous?
- What Happened With the Accord Healthcare Levothyroxine Recall?
- The NP Thyroid Scandal and What It Revealed About Quality Control
- What Should Patients and Caregivers Do Right Now?
- Could Your Thyroid Medication Be Unnecessary in the First Place?
- The Brain Health Connection That Gets Overlooked
- What Comes Next for Thyroid Medication Safety
- Conclusion
- Frequently Asked Questions
How Many Americans Take Levothyroxine, and Why Is Underdosing So Dangerous?
Levothyroxine ranked as the number one most commonly prescribed medication in the U.S. in 2023, with over 100 million prescriptions dispensed in a single year. Between 1997 and 2016, thyroid hormone use among American adults nearly doubled — from 4.1% to 8.0% — and annual expenditures ballooned from $1.1 billion to $3.2 billion. Women are five to nine times more likely than men to develop hypothyroidism, which means the population most affected by dosing failures skews heavily female and, given the demographics of thyroid disease, often older. The reason underdosing matters so much comes down to the drug’s narrow therapeutic index.
Unlike medications where a 10% variation in potency is clinically insignificant, levothyroxine requires precise dosing measured in micrograms. A pill that delivers 80 mcg instead of 100 mcg is not “close enough.” The body notices. Subpotent thyroid medication can cause fatigue, weight gain, depression, elevated cholesterol, and cardiovascular complications. For older adults, these symptoms are frequently misattributed to aging itself — or worse, to the early stages of dementia. A patient whose cognitive fog is actually caused by an underdosed thyroid pill may end up evaluated for Alzheimer’s disease when the real problem is sitting in their medicine cabinet.
What Happened With the Accord Healthcare Levothyroxine Recall?
The FDA initially issued the recall on June 20, 2025, and then upgraded it to Class II — indicating that the affected products could cause “temporary or medically reversible adverse health consequences” — on July 23, 2025. The problem was identified during long-term stability testing, which revealed subpotent assay results. In plain terms, the tablets were degrading and delivering less thyroid hormone than they should. The recall covered seven different strengths: 25 mcg, 50 mcg, 88 mcg, 100 mcg, 112 mcg, 150 mcg, and 175 mcg. Nine lot numbers were ultimately included, with additional lots added as late as October 2025. The affected NDCs ranged from 16729-447 through 16729-456.
The tablets were manufactured by Intas Pharmaceuticals in India and distributed by Accord Healthcare, based in North Carolina. Patients who suspected they had affected bottles were directed to call a recall hotline at 1-855-297-6127, available Monday through Friday from 9 AM to 5 PM EST. However, the American Thyroid Association was careful to warn patients not to abruptly stop taking their medication, even if they believed their supply was affected. Suddenly discontinuing thyroid hormone replacement can trigger a dangerous rebound in symptoms, including severe hypothyroidism. The guidance was clear: contact your provider, get a replacement prescription from a different manufacturer, and do not simply go without. this is especially critical for older adults or those with existing cardiovascular disease, where abrupt thyroid hormone withdrawal can provoke cardiac events.
The NP Thyroid Scandal and What It Revealed About Quality Control
The Accord recall was troubling, but the NP Thyroid debacle was arguably worse. Acella Pharmaceuticals produced NP Thyroid, a desiccated thyroid medication that some patients and prescribers prefer over synthetic levothyroxine because it contains both T3 and T4 hormones. Between May 2018 and April 2021, multiple lots of NP Thyroid were found to contain inconsistent levels of active thyroid hormones — some batches had too much, others too little. The investigation uncovered a startling fact: Acella had no quality control unit and had failed to adequately monitor active ingredient levels during manufacturing.
The resulting class action led to a $46.5 million total settlement, with approximately $41.4 million available to the class of affected patients. Individual payouts ranged from $10 to $50 per eligible class member — modest sums that reflect the size of the class rather than the seriousness of the harm. Attorney fees were capped at $5 million. Anyone in the United States who received an NP Thyroid prescription between May 12, 2018 and April 30, 2021 was eligible to file a claim through the official settlement website at nptsettlement.com. For patients who spent those years struggling with unexplained symptom fluctuations — feeling fine one month, then crashing the next — the settlement confirmed what they had experienced was real and was caused by the medication itself.
What Should Patients and Caregivers Do Right Now?
If you or someone you care for takes levothyroxine, the first step is practical: check the bottle. Look at the manufacturer name and the lot number printed on the label. The Accord Healthcare recall affects lot numbers D2400536, D2300325, D2400679, D2300087, D2300092, D2300104, D2300076, D2300042, and D2300045. If your lot number matches, do not throw the bottle away and do not stop taking the medication cold. Call your prescriber’s office and ask for a replacement prescription specifying a different manufacturer. Pharmacies can and do carry levothyroxine from multiple generic manufacturers, and your provider can note “do not substitute” with a preferred brand if needed.
The tradeoff here is worth understanding. Brand-name levothyroxine — most commonly Synthroid — tends to cost more but has historically maintained tighter manufacturing controls. Generic levothyroxine is significantly cheaper and, for most patients, works identically. But “identically” depends on consistent potency, which is exactly what the Accord recall called into question. Some endocrinologists recommend that patients stick with the same manufacturer once they find a version that works well for them, precisely because small potency differences between generics can cause symptoms in sensitive individuals. For older adults with cognitive concerns, this consistency matters more than it might for a younger, otherwise healthy patient. The cost difference between brand and generic may be worth discussing with a provider, particularly if a patient has experienced unexplained symptom shifts after a pharmacy switch.
Could Your Thyroid Medication Be Unnecessary in the First Place?
This question sounds provocative, but it is grounded in peer-reviewed research. A Yale School of Medicine analysis found that as many as 90% of levothyroxine users may have been unnecessarily prescribed the drug. A separate study published in JAMA Internal Medicine found that 60% of patients started on levothyroxine had subclinical hypothyroidism — a condition where TSH levels are mildly elevated but the patient may have no symptoms — and 30% had entirely normal thyroid function at the time the prescription was written. The limitation here is important: “unnecessarily prescribed” does not mean “should stop taking it immediately.” Many patients who were started on levothyroxine for borderline lab values have now been on it for years.
Their bodies have adjusted. The hypothalamic-pituitary-thyroid axis may have downregulated its own hormone production in response to the external supply. Stopping abruptly can cause genuine hypothyroidism even in someone who never truly needed the drug to begin with. The appropriate response is not panic — it is a careful conversation with an endocrinologist about whether a supervised tapering trial might be warranted. For patients with dementia or cognitive impairment, this conversation should include their caregiver, because the symptoms of thyroid withdrawal can easily be mistaken for worsening dementia.
The Brain Health Connection That Gets Overlooked
Thyroid hormone plays a direct role in brain function. It influences myelination, neurotransmitter synthesis, and cerebral blood flow. Studies have consistently linked both overt and subclinical hypothyroidism to increased risk of cognitive impairment and, in some populations, dementia.
When a patient with mild cognitive complaints is taking a subpotent thyroid pill, their brain is being quietly starved of a hormone it needs to function. The tragedy is that this is an entirely reversible cause of cognitive decline — if it is caught. A caregiver who notices increased confusion, sluggishness, or withdrawal in someone taking levothyroxine should ask the prescribing physician to recheck TSH and free T4 levels, not assume the decline is simply the disease progressing.
What Comes Next for Thyroid Medication Safety
The back-to-back failures at Acella and Accord have prompted calls for tighter FDA oversight of thyroid medication manufacturing, particularly for products sourced from overseas facilities. Currently, the FDA inspects foreign manufacturing plants on a rotating basis, but critics argue the inspection cadence is insufficient for a drug with such a narrow therapeutic window taken by tens of millions of people.
Whether those calls translate into regulatory action remains uncertain. In the meantime, patients and caregivers have a concrete defense: regular lab monitoring. A TSH check every six to twelve months — or sooner if symptoms change — remains the simplest way to catch a potency problem before it causes lasting harm.
Conclusion
Levothyroxine is not just another prescription — it is the most commonly prescribed drug in America, and its users depend on precise, consistent dosing for their metabolic, cardiovascular, and cognitive health. The 2025 Accord Healthcare recall of more than 160,000 bottles of subpotent tablets, combined with the $46.5 million NP Thyroid settlement, makes clear that the manufacturing pipeline for this critical medication has real and recurring vulnerabilities. For older adults and those with cognitive concerns, the stakes are compounded: undertreated hypothyroidism can mimic or worsen dementia, and the symptoms of a subpotent pill are easily misattributed to aging or neurodegeneration. The practical steps are straightforward.
Check your lot numbers. Talk to your prescriber about manufacturer consistency. Get TSH levels monitored regularly, and do not assume that a stable prescription means a stable product. If you were affected by the NP Thyroid quality failures between 2018 and 2021, visit nptsettlement.com to check your eligibility. And if you or a loved one has experienced unexplained cognitive changes while on thyroid medication, ask the question that too few people think to ask: is the pill actually delivering what it promises?.
Frequently Asked Questions
How do I check if my levothyroxine is part of the 2025 Accord Healthcare recall?
Look at the label on your prescription bottle for the manufacturer name and lot number. The recall affects levothyroxine manufactured by Intas Pharmaceuticals for Accord Healthcare, with lot numbers D2400536, D2300325, D2400679, D2300087, D2300092, D2300104, D2300076, D2300042, and D2300045. You can also call the recall hotline at 1-855-297-6127 Monday through Friday, 9 AM to 5 PM EST.
Should I stop taking my levothyroxine if I think it might be subpotent?
No. The American Thyroid Association has specifically advised patients not to abruptly stop taking their thyroid medication. Contact your healthcare provider to get a replacement prescription from a different manufacturer, and continue taking your current supply until the replacement is available.
Am I eligible for the NP Thyroid settlement?
If you received a prescription for NP Thyroid in the United States between May 12, 2018 and April 30, 2021, you may be eligible for a payment of $10 to $50. Visit nptsettlement.com for details on filing a claim.
Can underdosed thyroid medication cause cognitive decline?
Yes. Thyroid hormone is essential for brain function, including neurotransmitter synthesis and cerebral blood flow. Undertreated hypothyroidism — whether from an inadequate dose or a subpotent pill — can cause cognitive fog, memory problems, and slowed thinking that may be mistaken for early dementia. The good news is that this type of cognitive decline is typically reversible once proper thyroid levels are restored.
Is brand-name Synthroid safer than generic levothyroxine?
Brand-name products have historically maintained tighter manufacturing controls, but generics are held to the same FDA potency standards. The key issue is consistency — switching between different generic manufacturers can introduce small potency variations that affect sensitive patients. Talk to your prescriber about specifying a single manufacturer if you have experienced symptoms after a pharmacy switch.
